Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.41 |
| ▸ | PIM1 | P11309 | 4/20 | 0.41 |
| ▸ | PRKACA | P17612 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.41 |
| ▸ | CLK2 | P49760 | 3/20 | 0.41 |
| ▸ | CDK7 | P50613 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | PRKX | P51817 | 3/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.41 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858300 | 0.85 | AXL (0.44) | CDC7MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL1267952 | 0.84 | AXL (0.48) | CDC7MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL21872999 | 0.81 | MAP2K1 (0.41) | CDC7MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL26696379 | 0.81 | CDC7 (0.46) | CDC7AXLMAPTGRM8GRM4 | |
| SCHEMBL857039 | 0.80 | MAPT (0.49) | CDC7GSK3BCDK9DYRK1AAXL | |
| SCHEMBL857047 | 0.80 | MAPT (0.46) | CDC7MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL22978447 | 0.79 | GRM8 (0.46) | CDC7MAP4K4DYRK1ACLK4CDK8 | |
| SCHEMBL1268047 | 0.79 | CSF1R (0.50) | CDC7MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL858184 | 0.79 | AXL (0.48) | CDC7MAP4K4PIM1PRKACAGSK3B | |
| SCHEMBL878759 | 0.77 | MET (0.42) | CDC7MAP4K4PIM1PRKACAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | CDC7 2303/4885MAP4K4 3531/4885PIM1 1036/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | CDC7 2303/4885MAP4K4 3531/4885PIM1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.